Objective To investigate the clinical efficacy of hydrocortisone in the treatment of refractory pneumonia caused by pneumonia and its effect on inflammation. Methods 80 children with refractory pneumonia mycoplasma pneumonia who were treated in our hospital from February 2017 to February 2019 were divided into two groups according to the random number table method, 40 cases in each group. The control group was treated with azithromycin, and the study group was treated with azithromycin combined with hydrocortisone. The disappearance time of clinical symptoms/signs, the level of inflammation before and after treatment [C-reactive protein (CRP), procalcitonin (PCT)] and the incidence of adverse reactions were compared. Results The disappearance time, fever time, disappearance time of cough, disappearance time of X-ray lung shadow and disappearance time of wheezing in the study group were shorter than those in the control group, the difference was statistically significant (P<0.05). Compared to before treatment, the serum CRP and PCT expressions of the two groups were decreased after 2 weeks of treatment, and the study group was lower than that of the control group (P<0.05). The total incidence of adverse reactions in the study group was slightly higher than that of the control group. The difference was not statistically significant. Conclusion The clinical efficacy of hydrocortisone in the treatment of refractory pneumonia mycoplasma pneumonia in children is significant, which can further alleviate the clinical symptoms/signs of children, reduce the level of inflammation, and have fewer adverse reactions. It is worth promoting.
Refractory pneumonia mycoplasma pneumonia